CR10996A - Metodo de tratamiento del cancer mediante administracion de combinaciones de il-18 humana - Google Patents

Metodo de tratamiento del cancer mediante administracion de combinaciones de il-18 humana

Info

Publication number
CR10996A
CR10996A CR10996A CR10996A CR10996A CR 10996 A CR10996 A CR 10996A CR 10996 A CR10996 A CR 10996A CR 10996 A CR10996 A CR 10996A CR 10996 A CR10996 A CR 10996A
Authority
CR
Costa Rica
Prior art keywords
human
treatment method
cancer treatment
combination administration
combinations
Prior art date
Application number
CR10996A
Other languages
English (en)
Inventor
Zdenka Haskova
Zdenka Ludmila Jonak
Stephen H Trulli
Margaret Whitacre
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39788932&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR10996(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of CR10996A publication Critical patent/CR10996A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invesion se refiere en general al uso d combinaciones de la IL-18 humana en el tratamiento de diversas formas de tumores solidos y linfomas. En particular, la presente invension se refiere a: (1) combinaciones de la IL-18 humana con anticuerpos monoclonales contra antigenos que se expresan en la superficie de cedulas cancerosas; y (2) combinaciones de IL-18 humana con agentes terapeuticas.
CR10996A 2007-03-23 2009-08-26 Metodo de tratamiento del cancer mediante administracion de combinaciones de il-18 humana CR10996A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89685507P 2007-03-23 2007-03-23
US95200207P 2007-07-26 2007-07-26

Publications (1)

Publication Number Publication Date
CR10996A true CR10996A (es) 2009-11-12

Family

ID=39788932

Family Applications (2)

Application Number Title Priority Date Filing Date
CR10996A CR10996A (es) 2007-03-23 2009-08-26 Metodo de tratamiento del cancer mediante administracion de combinaciones de il-18 humana
CR11075A CR11075A (es) 2007-03-23 2009-10-23 Combinado de humano il-18 y anticuerpo anti cd20 para el tratamiento del cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
CR11075A CR11075A (es) 2007-03-23 2009-10-23 Combinado de humano il-18 y anticuerpo anti cd20 para el tratamiento del cancer

Country Status (21)

Country Link
US (4) US20080274078A1 (es)
EP (3) EP2136841A4 (es)
JP (2) JP2010522200A (es)
KR (2) KR20100015798A (es)
CN (1) CN101678102A (es)
AR (2) AR065803A1 (es)
AU (2) AU2008231114A1 (es)
BR (2) BRPI0808943A2 (es)
CA (2) CA2681851A1 (es)
CL (2) CL2008000818A1 (es)
CR (2) CR10996A (es)
DO (2) DOP2009000208A (es)
EA (2) EA200970884A1 (es)
IL (2) IL200525A0 (es)
MA (2) MA31265B1 (es)
MX (2) MX2009010269A (es)
NZ (1) NZ579179A (es)
PE (2) PE20090190A1 (es)
SG (1) SG171674A1 (es)
TW (2) TW200906436A (es)
WO (2) WO2008118733A2 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2399148A1 (en) * 2000-02-10 2001-08-16 Abbott Laboratories Antibodies that bind human interleukin-18 and methods of making and using
US7968684B2 (en) 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
PE20090190A1 (es) * 2007-03-23 2009-03-22 Smithkline Beecham Corp Combinacion de anticuerpos anti-cd20 y polipeptidos de il-18
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
HUE047952T2 (hu) 2014-04-25 2020-05-28 Pf Medicament Ellenanyag-drog konjugátum és alkalmazása rák kezelésében történõ alkalmazásra
HRP20190888T8 (hr) 2014-04-25 2019-10-04 Pierre Fabre Médicament Konjugat antitijela za igf-1r i lijeka i njegova upotreba u liječenju karcinoma
KR101940430B1 (ko) * 2014-08-07 2019-01-18 가꼬우호우징 효고 이카다이가쿠 Il-18과 분자 표적 항체를 병용하는 암 치료약
WO2016126615A1 (en) * 2015-02-03 2016-08-11 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
WO2022115946A1 (en) * 2020-12-02 2022-06-09 The Royal Institution For The Advancement Of Learning/Mcgill University Therapeutic applications of type 1 insulin-like growth factor (igf-1) receptor antagonists
WO2025033330A1 (ja) * 2023-08-04 2025-02-13 医療革新国際連携株式会社 キマーゼ阻害剤と免疫療法の併用による抗腫瘍療法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69519454T2 (de) 1994-07-14 2001-05-03 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo, Okayama Protein, das Interferon-Gamma Herstellung induziert und monoklonaler Antikörper dagegen
JP4004088B2 (ja) 1995-09-26 2007-11-07 株式会社林原生物化学研究所 免疫担当細胞においてインターフェロン−γの産生を誘導する蛋白質
TW464656B (en) 1994-11-15 2001-11-21 Hayashibara Biochem Lab Interferon-gamma production inducing polypeptide monoclonal antibody, and agent for interferon-gamma susceptive disease
US7135458B1 (en) * 1995-11-15 2006-11-14 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interferon-γ inducing polypeptide, pharmaceutical composition thereof, monoclonal antibody thereto, and methods of use
US5680795A (en) 1995-07-05 1997-10-28 Norco Inc. Mechanical drive assembly incorporating counter-spring biassed radially-adjustable rollers
JP4024366B2 (ja) * 1996-11-29 2007-12-19 株式会社林原生物化学研究所 ポリペプチド
US6787132B1 (en) * 1997-12-04 2004-09-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Combined chemo-immunotherapy with liposomal drugs and cytokines
TWI227136B (en) * 1998-05-21 2005-02-01 Smithkline Beecham Corp Novel pharmaceutical composition for the prevention and/or treatment of cancer
PL366134A1 (en) * 2000-06-15 2005-01-24 Smithkline Beecham Corporation Method for preparing a physiologically active il-18 polypeptide
US20020094323A1 (en) * 2000-10-12 2002-07-18 Kristoffer Hellstrand Methods and compositions for promoting the maturation of monocytes
WO2003068821A2 (en) * 2002-02-14 2003-08-21 Immunomedics, Inc. Anti-cd20 antibodies and fusion proteins thereof and methods of use
WO2003072736A2 (en) * 2002-02-21 2003-09-04 Duke University Reagents and treatment methods for autoimmune diseases
EP2298338B1 (en) * 2002-09-16 2012-08-22 Agennix Incorporated Lactoferrin compositions and methods of treatment of skin wounds
KR20050073488A (ko) * 2002-10-08 2005-07-13 이뮤노메딕스, 인코오포레이티드 Ⅲ종 항-ｃｅａ 단클론 항체들 및 치료제들을 이용한 조합치료법
BRPI0315295C1 (pt) * 2002-10-17 2021-05-25 Genmab As anticorpo monoclonal humano isolado, célula hospedeira procariótica, composição farmacêutica, molécula biespecífica, usos de um anticorpo, métodos in vitro de detectar a presença de antígeno de cd20 ou uma célula que expressa cd20 em uma amostra, kit, e, vetor de expressão
US7534427B2 (en) * 2002-12-31 2009-05-19 Immunomedics, Inc. Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
EP2261244A3 (en) * 2003-04-15 2011-02-23 Glaxosmithkline LLC Human il-18 substitution mutants and their conjugates
US20050075277A1 (en) * 2003-07-10 2005-04-07 Agennix Incorporated Use of lactoferrin in prophylaxis against infection and/or inflammation in immunosuppressed subjects
CA2534639C (en) * 2003-07-31 2013-07-30 Immunomedics, Inc. Anti-cd19 antibodies
CA2604222A1 (en) * 2005-04-18 2006-10-26 Novo Nordisk A/S Il-21 variants
WO2007009469A2 (en) * 2005-07-21 2007-01-25 Genmab A/S Potency assays for antibody drug substance binding to an fc receptor
WO2008008981A1 (en) * 2006-07-13 2008-01-17 Zymogenetics, Inc. Interleukin 21 and tyrosine kinase inhibitor combination therapy
EP2059253A4 (en) * 2006-09-14 2011-09-14 Univ Pennsylvania MODULATION OF T LYMPHOCYTES REGULATORS BY HUMAN IL-18
PE20090190A1 (es) * 2007-03-23 2009-03-22 Smithkline Beecham Corp Combinacion de anticuerpos anti-cd20 y polipeptidos de il-18

Also Published As

Publication number Publication date
KR20100014530A (ko) 2010-02-10
EP2136841A4 (en) 2010-07-07
AU2008231114A1 (en) 2008-10-02
MA31265B1 (fr) 2010-03-01
KR20100015798A (ko) 2010-02-12
EA200970884A1 (ru) 2010-04-30
TW200906436A (en) 2009-02-16
CL2008000842A1 (es) 2008-10-17
MX2009010269A (es) 2009-10-12
IL200525A0 (en) 2010-04-29
AR065803A1 (es) 2009-07-01
WO2008118736A1 (en) 2008-10-02
AU2008231025A1 (en) 2008-10-02
WO2008118733A2 (en) 2008-10-02
CA2681827A1 (en) 2008-10-02
CN101678102A (zh) 2010-03-24
JP2010522200A (ja) 2010-07-01
EP2136841A2 (en) 2009-12-30
IL200863A0 (en) 2010-05-17
DOP2009000208A (es) 2010-03-31
US20090035258A1 (en) 2009-02-05
EP2129398A4 (en) 2010-04-21
MA31264B1 (fr) 2010-03-01
EP2338514A1 (en) 2011-06-29
NZ579179A (en) 2011-12-22
CR11075A (es) 2010-03-22
TW200904469A (en) 2009-02-01
CA2681851A1 (en) 2008-10-02
MX2009010271A (es) 2009-10-12
SG171674A1 (en) 2011-06-29
AR065818A1 (es) 2009-07-01
PE20090190A1 (es) 2009-03-22
PE20090184A1 (es) 2009-03-22
US20080274078A1 (en) 2008-11-06
US20100111945A1 (en) 2010-05-06
US20100196310A1 (en) 2010-08-05
EP2129398A1 (en) 2009-12-09
EA200970885A1 (ru) 2010-02-26
CL2008000818A1 (es) 2008-09-26
WO2008118733A3 (en) 2008-11-27
BRPI0808943A2 (pt) 2014-08-26
BRPI0809079A2 (pt) 2019-03-06
DOP2009000220A (es) 2009-10-31
JP2010522239A (ja) 2010-07-01

Similar Documents

Publication Publication Date Title
CR10996A (es) Metodo de tratamiento del cancer mediante administracion de combinaciones de il-18 humana
MX2010000465A (es) Metodos y composiciones para el tratamiento de cancer, tumores y alteraciones relacionadas con tumores.
BR112019011450A2 (pt) células naturais killer modificadas e uso das mesmas
AR074203A1 (es) Terapia anti-angiogenesis para el tratamiento del cancer de mama. kit. uso.
CL2017001580A1 (es) Anticuerpo o fragmento de anticuerpo contra cd38 anticuerpo humanizado, conjugado del anticuerpo con un compuesto citotoxico composición farmacéutica con dichos anticuerpos uso de los anticuerpos para tratar cáncer o enfermedad autoinmune método para diagnosticar cáncer polinucleotido vector y célula huésped.
EA201070463A1 (ru) Комбинированная терапия с использованием конъюгатов антитело-лекарственное средство
AR074360A1 (es) Anticuerpo monoclonal o fragmento de union a antigeno del mismo composicion farmaceutica que lo comprende y su uso para preparar dicha composicion
EA201391351A1 (ru) Способы повышения эффективности folr1 терапии рака
NI201300119A (es) Uso del anticuerpo anti - cd19 inmunoconjugado con maitansinoide para el tratatamiento del síntoma tumores de células b.
ES2422605T3 (es) Anticuerpo contra klotho-beta para utilizar en el tratamiento de tumores, cáncer o trastornos proliferativos celulares
AR077866A1 (es) Terapia de combinacion de un anticuerpo cd20 afucosilado y bendamustina
CO7350624A2 (es) Inhibidores de la tirosina-quinasa de bruton
CR10143A (es) Antígenos de ácido des-n-acetil-siálico, anticuerpos para los mismos y métodos de uso en la terapia del cáncer
MX2010003815A (es) Terapia de combinacion de un anticuerpo anti-cd20 de tipo ii con un agente activo anti-bcl-2.
PH12020550598A1 (en) Methods and compositions for dosing of allogeneic chimeric antigen receptor t cells
CR20120310A (es) Anticuerpos neutralizadores contra el receptor de prolactina y su uso terapéutico
AR073717A1 (es) Anticuerpos anti-notch2 de murino y humano, y metodos de uso
MX353964B (es) Agentes terapeuticos y usos de los mismos.
UA105760C2 (uk) Антитіло проти bst2
BR112015027474A8 (pt) anticorpo, composição, método de tratamento do paciente que sofre de câncer e uso de um anticorpo.
MX2022014231A (es) Conjugados de anticuerpo-farmaco que se enfocan a la uparap.
WO2010054377A3 (en) Fully human antibodies against n-cadherin
BR112013033544A2 (pt) dosagem e administração de anticorpos anti-erbb3 em combinação com paclitaxel para tratamento de cânceres ginecológicos
AR081321A1 (es) N-cadherina: un blanco para el diagnostico y la terapia del cancer
BRPI0702847A (pt) formas de dosagem unitária de temozolomida

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)